Among the categorical variables, only interferon beta-1b treatment was significantly associated with changes in anti-TPO titres (p=0.001), but not sex, smoking/drinking, abnormal TFTs on admission, baseline COVID-19 severity, baseline anti-TPO positivity, baseline lymphopenia or comorbidities. The gene discussed is TPO; the disease is COVID-19.